The immunopathogenesis of narcolepsy type 1
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Originalsprog | Engelsk |
---|---|
Tidsskrift | Nature Reviews Immunology |
Vol/bind | 24 |
Sider (fra-til) | 33-48 |
ISSN | 1474-1733 |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
The authors thank L. Chatenoud, R. Mallone and D. Dunia for their feedback on the manuscript, and T. Sarkanen and D. Frieser for their help with Supplementary Fig. and Supplementary Fig. , respectively. R.S.L. is supported by Institut Universitaire de France and grants from Fondation pour la Recherche Médicale, the Agence Nationale de la Recherche (BETPSY RHU consortium, NARCOMICS consortium and ANR-18-CE17-0014-03). Y.D. is supported by grants from Agence Nationale de la Recherche (NARCOMICS consortium and ANR-18-CE17-0014-03). D.L. is supported by a PRIMA grant from the Swiss National Science Foundation (PR00P3_185742). B.R.K. is supported by the Lundbeck Foundation (grant R344-2020-749), and a Carlsberg Foundation Young Researcher Fellowship. E.J.M.’s research on narcolepsy is supported by National Institutes of Health grant R01 AI144798.
Funding Information:
R.S.L. has received grant support from GlaxoSmithKline and Roche and has consulted for Merck, Novartis, Biogen and Sanofi-Genzyme. B.R.K. has consulted for UCB Pharma, Lundbeck, Gubra and Orexia Therapeutics, has submitted patent applications within the field of narcolepsy and is a founder of the University of Copenhagen spin-out company Ceremedy ApS. Y.D. is a consultant for and has participated in advisory boards for Jazz Pharmaceuticals, UCB Pharma, Avadel, Idorsia, Orexia, Takeda and Bioprojet. In the last 3 years, E.J.M. received grant support from, is a consultant for or has participated in advisory boards for Apple, Avadel, Axsome, Huami, Harmony, Idorsia, Jazz Pharmaceuticals, Orexia/Centessa, Sunovion and Takeda. D.L. declares no competing interests.
Publisher Copyright:
© 2023, Springer Nature Limited.
ID: 360030070